Clinical Trials
MALT1 Inhibition Reprograms Glioblastoma Microenvironment and Enhances Temozolomide Chemosensitivity
Mayo ClinicMayo Clinic

Mayo Clinic researchers have identified MALT1 protein inhibition as a novel therapeutic strategy to overcome immunosuppression and enhance treatment response in glioblastoma. In preclinical research published in Nature Communications, targeting the enzymatic activity of MALT1 successfully reprogrammed tumor-associated immune cells, shifting them from a protective, pro-tumor state to an active antitumor immune phenotype and slowing tumor growth.
Additionally, combining MALT1 inhibition with temozolomide—the standard chemotherapy used in glioblastoma management—enhanced chemosensitivity and substantially increased median survival in a preclinical model compared to temozolomide monotherapy alone. Glioblastoma remains the most common and aggressive primary malignant brain tumor in adults, almost universally recurring despite trimodal therapy consisting of surgical resection, radiotherapy, and chemotherapy. These preclinical findings demonstrate that MALT1 inhibition can disrupt tumor immune evasion and augment current standard treatments, though further studies are required to determine which glioblastoma subtypes will derive the greatest clinical benefit before advancing to human trials.
Key Takeaways
- Preclinical inhibition of MALT1 enzymatic activity reprograms the glioblastoma microenvironment from immunosuppressive to antitumor, resulting in slowed tumor growth.
- Combining MALT1 inhibition with standard temozolomide chemotherapy substantially increased median survival compared to temozolomide monotherapy in a preclinical glioblastoma model.
Read the original sourceMayo Clinic
